BELLEVUE, Wash.--(BUSINESS WIRE)--SCOLR Pharma, Inc. (AMEX: DDD) today announced that it has received a special protocol assessment from the Food and Drug Administration (FDA) to guide the design of its Phase III pivotal dental pain study to support a New Drug Application (NDA) for an over-the-counter (OTC) 12-hour extended-release (ER) ibuprofen product. SCOLR plans to initiate the study in the next 60 days.
